CBD Global Sciences Provides Update on Filing Q2 Financial Statements and MD&A

DENVER, CO / ACCESSWIRE / August 31, 2020 / CBD Global Sciences Inc. (CSE:CBDN) (the “Company“) would like to provide an update on the status of the filing of its interim financial statements, accompanying management discussion and analysis and related CEO and CFO certifications for the period ended June 30, 2020 (the “Interim Filings“).

On May 20, 2020, the Canadian Securities Administrators (“CSA“) issued a notice stating that securities regulators will be providing coordinated relief consisting of a 45-day extension for certain periodic filings required to be made during the period of June 2, 2020 to August 31, 2020, as a result of the COVID-19 pandemic. Accordingly, the Alberta Securities Commission (“ASC“) has enacted Instrument 51-519 – Temporary Exemption from Certain Corporate Finance Requirements (“ASC 51-519“).

The Company will be relying on the temporary exemption pursuant to ASC 51-519 in respect to the following provisions:


  Subscribe to news from
CBD Global Sciences

Be the first to know when breaking news are released.



  • the requirement to file interim financial statements for the six month period ended June 30, 2020 (the “Interim Financial Statements“) within 60 days of the Company’s second quarter as required by section 4.4(b) of NI 51-102

  • the requirement to file management discussion and analysis (the “Interim MD&A”) for the period covered by the Interim Financial Statements within 60 days of the Company’s second quarter as required by section 5.1(2) of NI 51-102; and

  • the requirement to file certifications of the Interim Financial Statements (the “Certificates” and together with the Interim Financial Statements and Interim MD&A, the “Interim Filings“) pursuant to section 5.1 of National Instrument 52-109.

Other than as disclosed in the Company’s press releases, there have not been any material business developments since the date that the last financial statements of the Company were filed.

The Company is continuing to work diligently and expeditiously with its auditors to file the Interim Filings together on or before October 13, 2020. In the interim, management and other insiders of the Company are subject to a trading black-out policy as described, in principle, in section 9 of National Policy 11-207 – Failure to File Cease Trade Orders and Revocations in Multiple Jurisdictions.

ABOUT CBD GLOBAL SCIENCES INC.

CBD Global Sciences Inc., is a vertically integrated hemp-based CBD producer, extractor, and branding investment vehicle which currently owns two product categories, branded under the name AETHICS (www.aethics.com) and CANNAOIL (www.cannaoilshop.com), which include CBD Oil tinctures (liquid products), CBD capsules, CBD topicals and CBD hydration products. CBD Global’s hemp-derived CBD extracts are sold through select distributors, brick and mortar retailers, and online.

CBD Global Sciences, through its wholly owned subsidiary, Strasburg Pharms, grows and operates irrigated land in Colorado that grows hemp with only all-natural Colorado water, soil, sun and nutrients that is NEVER sprayed with pesticides or chemicals. Our genetics are hand selected and maintained to present the best cannabinoid profile with extremely high CBD. The extraction/processing facility, operated by CBD Global, is located approximately 40 minutes from the farm.

For further information, please contact Bruce Nurse, Investor Relations, (303) 919-2913, info@cbdglobalsciences.com.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAS REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This news release includes certain “forward-looking statements” under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to, statements with respect to future developments and the business and operations of the Corporation after the CSE listing. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to general business, economic, competitive, political and social uncertainties; and delay or failure to receive board, shareholder or regulatory approvals. Readers should not place undue reliance on forward-looking statements. The Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

NOT FOR DISTRIBUTION OR DISSEMINATION INTO THE UNITED STATES

SOURCE: CBD Global Sciences Inc.

View source version on accesswire.com:
https://www.accesswire.com/604091/CBD-Global-Sciences-Provides-Update-on-Filing-Q2-Financial-Statements-and-MDA